公开(公告)号：US20210371394A1

公开(公告)日：2021-12-02

申请号：US17322409

申请日：2021-05-17

Applicant: Novartis AG

Inventor： Zichen JIA ,  Philipp LUSTENBERGER ,  Marie MEYER ,  Massimo MORATTO

IPC: C07D401/06

Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.

公开(公告)号：US20220175682A1

公开(公告)日：2022-06-09

申请号：US17600203

申请日：2020-04-02

Applicant: Novartis AG

Inventor： Nicole BIERI ,  Elodia DI RENZO ,  David HOOK ,  Jennifer Claire HOOTON ,  Markus KRUMME ,  Steffen LANG ,  Franck MALLET ,  Massimo MORATTO ,  Joerg OGORKA ,  Jim PARKS ,  Dale W. PLOEGER ,  Norbert RASENACK ,  Hendrik SCHNEIDER ,  Lipa SHAH ,  Stefan STEIGMILLER ,  Gordon STOUT ,  Patrick TRITSCHLER ,  Fabian WEBER

IPC: A61K9/48 ,  A61K9/16 ,  A61K31/506

Abstract: The present invention relates to methods of preparing pharmaceutical products, involving filling active pharmaceutical ingredient powders into pharmaceutical carriers with a vacuum assisted metering and filling device. The methods disclosed herein can be used in a continuous process, such as in a high-throughput process for producing a pharmaceutical product. The present invention further relates to a particular quality of the neat active pharmaceutical ingredient (API) HDM201, i.e. siremadlin, present as succinic acid co-crystal, which can be used in the methods of preparation of the present invention.

公开(公告)号：US20230265067A1

公开(公告)日：2023-08-24

申请号：US18168711

申请日：2023-02-14

Applicant: Novartis AG

Inventor： Zichen JIA ,  Philipp LUSTENBERGER ,  Marie MEYER ,  Massimo MORATTO

IPC: C07D401/06

CPC classification number: C07D401/06 ,  C07B2200/13

Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.